Your session is about to expire
← Back to Search
Bemcentinib + Pembrolizumab + Chemotherapy for Non-Small Cell Lung Cancer
Study Summary
This trial tests safety and effectiveness of a drug combo to treat advanced non-squamous lung cancer with or without STK11 mutations.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your doctor can measure your disease using specific guidelines.My cancer has a specific genetic mutation or rearrangement.I have had treatment for advanced lung cancer.My lung cancer is advanced or has spread, and cannot be cured with surgery.My advanced non-small cell lung cancer is confirmed and cannot be cured with surgery.I had radiation therapy less than 2 weeks ago or still have side effects.I have not had major surgery in the last 28 days or have fully recovered from it.I haven't had any systemic treatment for my advanced lung cancer.
- Group 1: Phase 1b Cohort 3: Bemcentinib Dose 3
- Group 2: Phase 1b Cohort 1: Bemcentinib Dose 1
- Group 3: Phase 1b Cohort 2: Bemcentinib Dose 2
- Group 4: Phase 2a Expansion Cohort: Bemcentinib (at 2 doses as determined from Phase 1b)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still vacancies in this clinical trial?
"Affirmative. According to clinicaltrials.gov, this trial is currently seeking enrolment of 64 participants from a single site. The initial posting date was December 14th 2022 and the data were last updated on April 18th 2023."
What is the current enrollment limit for this investigation?
"Affirmative. Data on clinicaltrials.gov indicates that the current recruitment of participants for this medical study commenced in December 14th, 2022 and was most recently updated April 18th, 2023. The trial is seeking to recruit 64 individuals from one site."
What aim is this medical experiment attempting to accomplish?
"The principal aim of this clinical trial, lasting for approximately 12 months, is to measure the Objective Response Rate (ORR) at 6 Months. Secondary goals include assessing Disease Control Rates (DCR), Area Under the Curve Within a Dosing Interval (AUC[0-t]), and Apparent Terminal Half-life (t1/2)."
Share this study with friends
Copy Link
Messenger